124 related articles for article (PubMed ID: 36606484)
21. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
22. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
23. An in vitro model to monitor natural killer cell effector functions against breast cancer cells derived from human tumor tissue.
Beelen NA; Ehlers FAI; Kooreman LFS; Bos GMJ; Wieten L
Methods Cell Biol; 2023; 173():133-153. PubMed ID: 36653080
[TBL] [Abstract][Full Text] [Related]
24. TGF-β regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression.
Huang CH; Liao YJ; Chiou TJ; Huang HT; Lin YH; Twu YC
Immunobiology; 2019 Sep; 224(5):649-658. PubMed ID: 31421859
[TBL] [Abstract][Full Text] [Related]
25. Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells.
Bonanni V; Antonangeli F; Santoni A; Bernardini G
J Immunother Cancer; 2019 Nov; 7(1):290. PubMed ID: 31699153
[TBL] [Abstract][Full Text] [Related]
26. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
Frazao A; Rethacker L; Jeudy G; Colombo M; Pasmant E; Avril MF; Toubert A; Moins-Teisserenc H; Roelens M; Dalac S; Maubec E; Caignard A
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912923
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Österborg A; Lundqvist A
Eur J Immunol; 2015 Jun; 45(6):1783-93. PubMed ID: 25773885
[TBL] [Abstract][Full Text] [Related]
28. Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization.
Powell AB; Yadavilli S; Saunders D; Van Pelt S; Chorvinsky E; Burga RA; Albihani S; Hanley PJ; Xu Z; Pei Y; Yvon ES; Hwang EI; Bollard CM; Nazarian J; Cruz CRY
J Transl Med; 2019 Sep; 17(1):321. PubMed ID: 31547819
[TBL] [Abstract][Full Text] [Related]
29. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.
He S; Yin T; Li D; Gao X; Wan Y; Ma X; Ye T; Guo F; Sun J; Lin Z; Wang Y
J Transl Med; 2013 Aug; 11():186. PubMed ID: 23937717
[TBL] [Abstract][Full Text] [Related]
30. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.
Lee JC; Lee KM; Kim DW; Heo DS
J Immunol; 2004 Jun; 172(12):7335-40. PubMed ID: 15187109
[TBL] [Abstract][Full Text] [Related]
31. Refurbishment of NK cell effector functions through their receptors by depleting the activity of nTreg cells in Dalton's Lymphoma-induced tumor microenvironment: an in vitro and in vivo study.
Tomar MS; Singh RK; Ulasov IV; Kaushalendra ; Acharya A
Cancer Immunol Immunother; 2023 Jun; 72(6):1429-1444. PubMed ID: 36460868
[TBL] [Abstract][Full Text] [Related]
32. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
33. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
[TBL] [Abstract][Full Text] [Related]
34. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.
Zemek RM; De Jong E; Chin WL; Schuster IS; Fear VS; Casey TH; Forbes C; Dart SJ; Leslie C; Zaitouny A; Small M; Boon L; Forrest ARR; Muiri DO; Degli-Esposti MA; Millward MJ; Nowak AK; Lassmann T; Bosco A; Lake RA; Lesterhuis WJ
Sci Transl Med; 2019 Jul; 11(501):. PubMed ID: 31316010
[TBL] [Abstract][Full Text] [Related]
35. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.
Pasero C; Gravis G; Guerin M; Granjeaud S; Thomassin-Piana J; Rocchi P; Paciencia-Gros M; Poizat F; Bentobji M; Azario-Cheillan F; Walz J; Salem N; Brunelle S; Moretta A; Olive D
Cancer Res; 2016 Apr; 76(8):2153-65. PubMed ID: 27197252
[TBL] [Abstract][Full Text] [Related]
36. Engineered Three-Dimensional Tumor Models to Study Natural Killer Cell Suppression.
Temples MN; Adjei IM; Nimocks PM; Djeu J; Sharma B
ACS Biomater Sci Eng; 2020 Jul; 6(7):4179-4199. PubMed ID: 33463353
[TBL] [Abstract][Full Text] [Related]
37. Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-β signaling pathway.
Zhao Y; Hu J; Li R; Song J; Kang Y; Liu S; Zhang D
Onco Targets Ther; 2015; 8():1553-9. PubMed ID: 26124672
[TBL] [Abstract][Full Text] [Related]
38. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
39. Natural Killer Cell Dysfunction in Obese Patients with Breast Cancer: A Review of a Triad and Its Implications.
Elaraby E; Malek AI; Abdullah HW; Elemam NM; Saber-Ayad M; Talaat IM
J Immunol Res; 2021; 2021():9972927. PubMed ID: 34212054
[TBL] [Abstract][Full Text] [Related]
40. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
